Should patients with mildly elevated LDL-cholesterol be treated with small doses of statins, and patients with high level of cholesterol with high doses of statins? Review article
Article Sidebar
Published:
Jun 30, 2016
Keywords:
dose of statin, LDL-cholesterol fraction, cardiovascular risk
Main Article Content
Abstract
The administered dose of statin is associated primarily with cardiovascular risk for particular patient. The greater the risk, the greater the dose of the drug generally – but this depends on many factors.
Article Details
How to Cite
Kuch , M., & Janiszewski , M. (2016). Should patients with mildly elevated LDL-cholesterol be treated with small doses of statins, and patients with high level of cholesterol with high doses of statins?. Medycyna Faktow (J EBM), 9(2(31), 100-101. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2242
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z., Catapano A.L., De Backer G. et al.: ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32: 1769-1818.
2. Perk J., De Backer G., Gohlke H. et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012; 33(13): 1635-1701.
3. Jones P., Kafonek S., Laurora I., Hunninghake D.: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J. Cardiol. 1998; 81(5): 582-587.
4. Jones P.H., Davidson M.H., Stein E.A. et al.; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003; 92(2): 152-160.
2. Perk J., De Backer G., Gohlke H. et al.: European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012; 33(13): 1635-1701.
3. Jones P., Kafonek S., Laurora I., Hunninghake D.: Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J. Cardiol. 1998; 81(5): 582-587.
4. Jones P.H., Davidson M.H., Stein E.A. et al.; STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am. J. Cardiol. 2003; 92(2): 152-160.